Coronavirus Drug Discovery and Development
As part of the international effort to slow and combat the spread of pandemic COVID-19, ImQuest BioSciences has testing capability to assess novel and repurposed antiviral therapeutic and prevention products for activity against coronaviruses. With BSL-2 and BSL-3 strains available for testing, with capacity for both targeted testing, range of action assessments, combination and resistance characterization and selection. Numerous assay endpoints are available for in vitro testing. As a preclinical contract research organization, with a specialized expertise in assessing novel anti-infective products, ImQuest is available to rapidly support our clients and partners in their development of novel molecules. Contact us to learn more about our capabilities and how we can assist in the rapid testing of your compounds.
These services are only a component of our antiviral services, specifically as a part of our respiratory virus programs. Additional services for influenza, respiratory syncytial virus, parainfluenza virus, human respiratory virus, adenovirus and measles virus are also available to assess range of action of antiviral agents.
As members of the scientific and infectious disease community, we recommend continued vigilance and preparation to slow the propagation of COVID-19 and protect high risk members of our communities. For additional information on COIVID-19 and prevention measures, please see these helpful resources: Johns Hopkins Coronavirus Resource Center, CDC COVID-19 Situation Summary. We strongly recommend following the guidance of the NIH and CDC in community efforts to prevent COVID-19.